Clinician and Institution Profile

Academic Institution (Hub-and-Spoke Model)

The Cleveland Clinic Main Campus

Cleveland, OH

Type of Facility: Academic

Type of Control: Voluntary non-profit

Total Staffed Beds: 1,326

Total Patient Revenue: $20,807,393,423

Total Discharges: 50,013

Total Patient Days: 367,453

LungVision^TM Acquisition: 2021

Fairview Hospital

Cleveland, OH

Type of Facility: Academic (Satellite Hospital)

Type of Control: Voluntary non-profit

Total Staffed Beds: 466

Total Patient Revenue: $1,968,777,773

Total Discharges: 24,027

Total Patient Days: 115,711

LungVision^TM Acquisition: 2022

 Joseph Cicenia, MD

Interventional Pulmonologist,

The Cleveland Clinic

Cleveland, OH

LungVision^TM Trained: 2019

Sonali Sethi, MD

Interventional Pulmonologist,

The Cleveland Clinic

Cleveland, OH

LungVision^TM Trained: 2019

Michael Machuzak, MD

Interventional Pulmonologist,

The Cleveland Clinic

Cleveland, OH

LungVision^TM Trained: 2019

Background

• LungVision™ prototype placed at The Cleveland Clinic Main Campus in 2019 for registry trial and product development
• Initially used standalone for advanced navigation and real-time, intraoperative imaging.
• Acquired Ethicon Monarch (2021) and Ion by Intuitive (2022) robotic bronchoscopy platforms, but IP team continues to use LungVision™ as standalone system for some cases and as real-time, intraoperative imaging adjunct to robotic platforms.
• LungVision™ system at The Cleveland Clinic Main Campus upgraded to full commercial system in 2021 upon purchase.
• Second LungVision™ system acquired for Fairview Hospital (satellite hospital) in 2022 justified due to cost savings over alternative advanced navigation platforms such as electromagnetic navigation and robotics.

Clinical and Financial Impact

Based on data presented by Joseph Cicenia, MD.¹

Takeaway

The Cleveland Clinic’s acquisition of LungVision™ AI-driven image guidance for both Main Campus and Fairfield Hospital enabled them to:

• Improve their diagnostic yield by 14.5% (from 74% to 88%) over superD and/or a pre-production version of LungVision™, which translates to an estimated 202 additional diagnosed individuals and $4.4M in incremental downstream revenue
• Save an estimated $2,700 per case when using LungVision™ standalone for navigation and real-time imaging compared with using a robotic bronchoscopy platform

Sources

^{¹Cicenia, J. (2023, August 24). The Cleveland Clinic Experience: Integrating Real-Time Image Guidance in a Hub-and-Spoke Model. American Association for Bronchology and Interventional Pulmonology 6th Annual Conference. Chicago, Illinois, USA. (bodyvisionmedical.com/videos/aabip-2023-lunchsymposium). ²Incremental downstream revenue based on number of additional diagnosed patients from increase in 14.5% diagnostic yield, assumptions that 50% of additional diagnosed patients diagnosed with cancer, 28% private payor / 72% Medicare-Medicaid payor mix, with 35% undergoing radiation therapy, 15% undergoing lung resection, 50% undergoing chemotherapy, 80% undergoing PET scans, 100% undergoing additional CT scans, and 100% undergoing pulmonary function test reimbursed at the national average for the appropriate CPT code. ³Based on estimated $2,000 increase in robotic per-case costs.}